Sol-Gel Technologies Ltd. (SLGL)

Market Cap	109.59M
Revenue (ttm)	3.88M
Net Income (ttm)	-14.92M
Shares Out	25.70M
EPS (ttm)	-0.65
PE Ratio	n/a
Forward PE	9.34
Dividend	n/a
Ex-Dividend Date	n/a

Volume	61,815
Open	4.30
Previous Close	4.22
Day's Range	4.22 - 4.48
52-Week Range	3.24 - 7.95
Beta	1.32
Analysts	Buy
Price Target	12.75 (+198.95%)
Earnings Date	May 11, 2023

About SLGL

Sol-Gel Technologies Ltd., a clinical stage specialty pharmaceutical company, focuses on developing and commercializing topical dermatological drug products based on its proprietary microencapsulation delivery system in Israel. The company's lead product candidates include Twyneo, a novel, once-daily, non-antibiotic topical cream which has completed Phase III clinical trials for the treatment of acne vulgaris; Epsolay, a once-daily topical cream that has completed Phase III clinical trials for the treatment of papulopustular rosacea; SGT-210, w...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Jan 23, 2018
• Employees: 53
• Stock Exchange: NASDAQ
• Ticker Symbol: SLGL

Analyst Forecast

According to 9 analysts, the average rating for SLGL stock is "Buy." The 12-month stock price forecast is $12.75, which is an increase of 198.95% from the latest price.

Price Target

$12.75

(198.95% upside)

Analyst Consensus: Buy